BR112016022055A2 - elementos de ligação ao tnf alfa - Google Patents

elementos de ligação ao tnf alfa

Info

Publication number
BR112016022055A2
BR112016022055A2 BR112016022055A BR112016022055A BR112016022055A2 BR 112016022055 A2 BR112016022055 A2 BR 112016022055A2 BR 112016022055 A BR112016022055 A BR 112016022055A BR 112016022055 A BR112016022055 A BR 112016022055A BR 112016022055 A2 BR112016022055 A2 BR 112016022055A2
Authority
BR
Brazil
Prior art keywords
binding elements
tnf binding
alpha tnf
tnf alpha
high potency
Prior art date
Application number
BR112016022055A
Other languages
English (en)
Inventor
Shamshiev Abdijapar
Kretzschmar Titus
Original Assignee
Cell Medica Switzerland Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Medica Switzerland Ag filed Critical Cell Medica Switzerland Ag
Publication of BR112016022055A2 publication Critical patent/BR112016022055A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

a presente invenção refere-se a elementos de ligação anti-tnf alfa e, em particular, a fragmentos de anticorpo monovalentes de ligação ao tnf alfa de alta potência que são altamente estáveis e solúveis. tais elementos de ligação podem ser usados no tratamento de doenças inflamatórias e outras, bem como em diagnóstico. também são fornecidos ácidos nucleicos, vetores, células e composições rela-cionados.
BR112016022055A 2014-03-26 2015-03-26 elementos de ligação ao tnf alfa BR112016022055A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14001123 2014-03-26
PCT/EP2015/056646 WO2015144852A1 (en) 2014-03-26 2015-03-26 Binding members to tnf alpha

Publications (1)

Publication Number Publication Date
BR112016022055A2 true BR112016022055A2 (pt) 2017-10-24

Family

ID=50389767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016022055A BR112016022055A2 (pt) 2014-03-26 2015-03-26 elementos de ligação ao tnf alfa

Country Status (13)

Country Link
US (3) US10233238B2 (pt)
EP (1) EP3122777B1 (pt)
JP (1) JP6832707B2 (pt)
KR (1) KR20160142849A (pt)
CN (1) CN106414498B (pt)
AU (1) AU2015238261B2 (pt)
BR (1) BR112016022055A2 (pt)
CA (1) CA2943445A1 (pt)
ES (1) ES2858482T3 (pt)
IL (1) IL248000B (pt)
MX (1) MX2016012479A (pt)
RU (1) RU2706551C2 (pt)
WO (1) WO2015144852A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
KR102622281B1 (ko) 2015-03-31 2024-01-08 소리소 파마슈티컬스 인크. 폴리펩티드
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3219727B1 (en) * 2016-03-17 2020-12-16 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof
EA039201B1 (ru) * 2016-03-17 2021-12-16 Нумаб Инновейшн Аг Антитела к фно и их функциональные фрагменты
CN108884156B (zh) * 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
EP3430044A1 (en) 2016-03-17 2019-01-23 Numab Innovation AG Anti-tnf alpha -antibodies and functional fragments thereof
CN106279406B (zh) * 2016-08-05 2019-08-20 南京必优康生物技术有限公司 猪皮中分离纯化的皮抑素g1的活性成分四连接素及其应用
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
CN109627334B (zh) * 2019-01-29 2020-07-17 康元医疗科技(大连)有限公司 一种纳米抗体、以该纳米抗体为配基的吸附剂及其用途
US20220389092A1 (en) * 2019-04-05 2022-12-08 The Regents Of The University Of California Methods and compositions involving chimeric binding polypeptides
JP2022538083A (ja) 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CA3144567A1 (en) 2019-06-21 2020-12-24 Scott Crowe Polypeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030811D1 (de) * 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
CA2573259A1 (en) * 2004-07-06 2006-02-09 Bioren Inc. High affinity anti-tnf-alpha antibodies and method
PL1888640T3 (pl) * 2005-05-18 2012-08-31 Ablynx Nv Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa
AU2006255415B2 (en) 2005-06-07 2011-10-06 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting TNFalpha
US7331518B2 (en) * 2006-04-04 2008-02-19 Factortrust, Inc. Transaction processing systems and methods
WO2008144753A2 (en) * 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Antibodies to tnf alpha and use thereof
ES2861592T3 (es) * 2008-06-25 2021-10-06 Novartis Ag Anticuerpos estables y solubles que inhiben el TNF
BRPI0915343A2 (pt) 2008-06-30 2015-10-27 Esbatech Alcon Biomed Res Unit polipeptídeos funcionalizados
US8722860B2 (en) 2009-04-16 2014-05-13 Abbvie Biotherapeutics Inc. Anti-TNF-α antibodies and their uses
WO2011084714A2 (en) * 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF

Also Published As

Publication number Publication date
CN106414498B (zh) 2020-09-08
AU2015238261A1 (en) 2016-10-06
KR20160142849A (ko) 2016-12-13
US10233238B2 (en) 2019-03-19
RU2016141561A3 (pt) 2018-08-23
RU2706551C2 (ru) 2019-11-19
WO2015144852A1 (en) 2015-10-01
US10995138B2 (en) 2021-05-04
IL248000A0 (en) 2016-11-30
AU2015238261B2 (en) 2020-11-19
US20190144532A1 (en) 2019-05-16
ES2858482T3 (es) 2021-09-30
EP3122777B1 (en) 2020-12-23
RU2016141561A (ru) 2018-04-27
IL248000B (en) 2021-12-01
CN106414498A (zh) 2017-02-15
US20170107282A1 (en) 2017-04-20
MX2016012479A (es) 2017-05-23
US20210332119A1 (en) 2021-10-28
JP6832707B2 (ja) 2021-02-24
JP2017515457A (ja) 2017-06-15
CA2943445A1 (en) 2015-10-01
EP3122777A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
BR112018067696A2 (pt) membros de ligação à pd-l1
ZA201905488B (en) Tigit- and light-based chimeric proteins
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12017500939A1 (en) T cell activating bispecific antigen binding molecules agiant folr1 and cd1
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
BR112018010429A2 (pt) ácidos nucleicos que se direcionam a ácidos nucleicos engenheirados
MY176332A (en) Multispecific antibody constructs
SG10201803384TA (en) Bispecific t cell activating antigen binding molecules
BR112017007765A2 (pt) composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
BR112017019914A2 (pt) receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b
MD4733B1 (ro) Anticorpi anti-TIGIT
MX2017001279A (es) Usos y composiciones de la flagelina.
MD4548B1 (ro) Polipeptide care se leagă de CX3CR1
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
MX2015005384A (es) Miembros de union para il-1 beta.
WO2015058861A8 (en) Bispecific constructs and their use in the treatment of various diseases
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
MY190647A (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
MX2019003077A (es) Anticuerpos novedosos contra el factor xi y sus usos.
EA201790503A1 (ru) Полипептиды, обладающие ксиланазной активностью, с большой глубиной переработки полисахаридов, содержащих ксилозу

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]